Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5441_Библиотеки_им_академика_М_И_Перельмана.pdf
xi
MeenakshiK.Chauhan Delhi Institute of Pharmaceutical Sciences and Research,
DPSRU, New Delhi, Delhi, India
Pawan Devangan Department of Pharmaceutics, National Institute of
Pharmaceutical Education and Research, Hyderabad, Telangana, India
Amit K. Dubey School of Pharmaceuticals and Population Health Informatics,
Faculty of Pharmacy, DIT University, Dehradun, India
DebasisGantayat School of Pharmaceuticals and Population Health Informatics,
Faculty of Pharmacy, DIT University, Dehradun, India
Rohit Garg Department of Pharmaceutics, National Institute of Pharmaceutical
Education and Research (NIPER) Raebareli, Lucknow, Uttar Pradesh, India
Arvind Gulbake Department of Pharmaceutics, National Institute of
Pharmaceutical Education and Research Guwahati, Guwahati, Assam, India
MadhuGupta Department of Pharmaceutics, Delhi Pharmaceutical Sciences and
Research University, New Delhi, India
Sourabh Jadhav Department of Pharmaceutics, National Institute of
Pharmaceutical Education and Research Guwahati, Guwahati, Assam, India
KeertiJain Drug Delivery and Nanomedicine Research Laboratory, Department
of Pharmaceutics, National Institute of Pharmaceutical Education and Research
(NIPER), Raebareli, Lucknow, Uttar Pradesh, India
Sanjay K. Jain Pharmaceutics Research Projects Laboratory, Department of
Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya
Pradesh, India
VineetK.Jain Department of Pharmaceutics, Delhi Pharmaceutical Sciences and
Research University (DPSRU), New Delhi, India
Lalit Lata Jha Department of Pharmaceutics, School of Pharmacy, Faculty of
Pharmacy, Parul University, Vadodara, Gujarat, India
NagphaseNakshatraJitendra Department of Pharmaceutics, National Institute
of Pharmaceutical Education and Research (NIPER) Raebareli, Lucknow, Uttar
Pradesh, India
MitJoshi Department of Pharmacology, Institute of Pharmacy, Nirma University,
Ahmedabad, India
JovitaKanoujia Amity Institute of Pharmacy, Amity University Madhya Pradesh
(AUMP), Gwalior, Madhya Pradesh, India
Chantibabu Katta Department of Pharmaceutics, National Institute of
Pharmaceutical Education and Research, Hyderabad, Telangana, India
AmanjotKaur Rayat Institute of Pharmacy, Ropar, Punjab, India
Editors and Contributors
xii
JaspreetKaur University Institute of Pharmaceutical Sciences, UGC Centre of
Advanced Studies (UGC-CAS), Panjab University, Chandigarh, India
Rayat Institute of Pharmacy, Ropar, Punjab, India
AnkitaKishore Amity Institute of Pharmacy, Amity University Madhya Pradesh
(AUMP), Gwalior, Madhya Pradesh, India
Harshita Krishnatreyya Department of Pharmaceutics, National Institute of
Pharmaceutical Education and Research Guwahati, Guwahati, Assam, India
Akhilesh Kumar Division of Medicine, ICAR-Indian Veterinary Research
Institute, Bareilly, Uttar Pradesh, India
AnkajKumar Department of Pharmaceutics, National Institute of Pharmaceutical
Education and Research Guwahati, Guwahati, Assam, India
Anoop Kumar Department of Pharmacology, Delhi Institute of Pharmaceutical
Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research
University (DPSRU), New Delhi, India
Sumit Kumar Department of Pharmaceutical Sciences, Central University
Haryana, Mahendragarh, Haryana, India
Soham Loharkar Department of Pharmaceutics, National Institute of
Pharmaceutical Education and Research, Hyderabad, Telangana, India
Jitender Madan Department of Pharmaceutics, National Institute of
Pharmaceutical Education and Research, Hyderabad, Telangana, India
AlokKumarMahor Institute of Pharmacy, Bundelkhand University, Jhansi, Uttar
Pradesh, India
Manju University Institute of Pharmaceutical Sciences, UGC Centre of Advanced
Studies (UGC-CAS), Panjab University, Chandigarh, India
Manshi Department of Pharmaceutics and Pharmacy Practice, SGT College of
Pharmacy, SGT University, Gurugram, Haryana, India
Neelesh Kumar Mehra Pharmaceutical Nanotechnology Research Laboratory,
Department of Pharmaceutics, National Institute of Pharmaceutical Education and
Research (NIPER), Ministry of Chemical and Family Welfare, Hyderabad,
Telangana, India
NeerajMishra Amity Institute of Pharmacy, Amity University Madhya Pradesh
(AUMP), Gwalior, Madhya Pradesh, India
Shashank Shekar Mishra School of Pharmaceuticals and Population Health
Informatics, Faculty of Pharmacy, DIT University, Dehradun, India
Gijith K. Mohan Drug Delivery and Nanomedicine Research Laboratory,
Department of Pharmaceutics, National Institute of Pharmaceutical Sciences and
Research (NIPER)—Raebareli, Lucknow, Uttar Pradesh, India
Editors and Contributors
xiii
AtulMourya Department of Pharmaceutics, National Institute of Pharmaceutical
Education and Research, Hyderabad, Telangana, India
Kalpana Nagpal Amity Institute of Pharmacy, Amity University, Noida, Uttar
Pradesh, India
PritishKumarPanda Pharmaceutics Research Projects Laboratory, Department
of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya
Pradesh, India
Bhoomika M. Patel National Forensic Sciences University, Gandhinagar,
Gujarat, India
Dhruvi Patel Department of Pharmaceutics, Parul Institute of Pharmacy &
Research, Faculty of Pharmacy, Parul University, Vadodara, Gujarat, India
HitarthiMayurPatel Department of Pharmaceutics, School of Pharmacy, Faculty
of Pharmacy, Parul University, Vadodara, Gujarat, India
Manisha Patel Drug Delivery and Nanomedicine Research Laboratory,
Department of Pharmaceutics, National Institute of Pharmaceutical Sciences and
Research (NIPER)—Raebareli, Lucknow, Uttar Pradesh, India
MeenakshiPatel Department of Pharmaceutics, School of Pharmacy, Faculty of
Pharmacy, Parul University, Vadodara, Gujarat, India
ParthPatel Drug Delivery and Nanomedicine Research Laboratory, Department
of Pharmaceutics, National Institute of Pharmaceutical Sciences and Research
(NIPER)—Raebareli, Lucknow, Uttar Pradesh, India
Anchal Pathak Drug Delivery and Nanomedicine Research Laboratory,
Department of Pharmaceutics, National Institute of Pharmaceutical Sciences and
Research (NIPER)—Raebareli, Lucknow, Uttar Pradesh, India
T. Pawan Kumar Department of Pharmaceutics, National Institute of
Pharmaceutical Education and Research, Hyderabad, Telangana, India
ShivamRamdasPawar Drug Delivery and Nanomedicine Research Laboratory,
Department of Pharmaceutics, National Institute of Pharmaceutical Education and
Research (NIPER), Raebareli, Lucknow, Uttar Pradesh, India
VibhootiPippola School of Pharmaceuticals and Population Health Informatics,
Faculty of Pharmacy, DIT University, Dehradun, India
Harvinder Popli Department of Pharmaceutics, Delhi Pharmaceutical Sciences
and Research University (DPSRU), New Delhi, India
Sarjana Raikwar Pharmaceutics Research Projects Laboratory, Department of
Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya
Pradesh, India
Editors and Contributors
xiv
Neha Raina Department of Pharmaceutics, Delhi Pharmaceutical Sciences and
Research University, New Delhi, India
V. Rajesh Department of Pharmaceutics, National Institute of Pharmaceutical
Education and Research Guwahati, Guwahati, Assam, India
Anjali Rajora Amity Institute of Pharmacy, Amity University, Noida, Uttar
Pradesh, India
Chetan Ram School of Pharmaceuticals and Population Health Informatics,
Faculty of Pharmacy, DIT University, Dehradun, India
Sunny Rathee Pharmaceutics Research Projects Laboratory, Department of
Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya
Pradesh, India
Sweta Roy Department of Pharmacology, Delhi Institute of Pharmaceutical
Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research
University (DPSRU), New Delhi, India
P. Saikiran Department of Pharmaceutics, National Institute of Pharmaceutical
Education and Research, Hyderabad, Telangana, India
Khyati Saini School of Pharmaceuticals and Population Health Informatics,
Faculty of Pharmacy, DIT University, Dehradun, India
Shivani Saraf Pharmaceutics Research Projects Laboratory, Department of
Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya
Pradesh, India
SonalSetya Department of Pharmaceutics and Pharmacy Practice, SGT College
of Pharmacy, SGT University, Gurugram, Haryana, India
Ruchika Sharma Centre for Precision Medicine and Pharmacy, Delhi
Pharmaceutical Sciences and Research University, New Delhi, India
Satish Shilpi School of Pharmaceuticals and Population Health Informatics,
Faculty of Pharmacy, DIT University, Dehradun, India
K.Shubham Delhi Institute of Pharmaceutical Sciences and Research, DPSRU,
New Delhi, Delhi, India
Prem Prakash Singh Institute of Pharmacy, Bundelkhand University, Jhansi,
Uttar Pradesh, India
Vaibhavi Srivastava Pharmaceutical Nanotechnology Research Laboratory,
Department of Pharmaceutics, National Institute of Pharmaceutical Education and
Research (NIPER), Ministry of Chemical and Family Welfare, Hyderabad,
Telangana, India
SushamaTalegaonkar Department of Pharmaceutics, School of Pharma Sciences,
DPSRU, New Delhi, Delhi, India
Editors and Contributors
xv
Soya Tarannum Drug Delivery and Nanomedicine Research Laboratory,
Department of Pharmaceutics, National Institute of Pharmaceutical Education and
Research (NIPER)—Raebareli, Lucknow, Uttar Pradesh, India
Darshana Tijare Department of Pharmaceutics, National Institute of
Pharmaceutical Education and Research, Hyderabad, Telangana, India
HarithasreeVeerabromma Department of Pharmaceutics, National Institute of
Pharmaceutical Education and Research, Hyderabad, Telangana, India
Awesh K. Yadav Department of Pharmaceutics, National Institute of
Pharmaceutical Education and Research (NIPER) Raebareli, Lucknow, Uttar
Pradesh, India
MonuYadav Amity Institute of Pharmacy, Amity University Gurgaon, Gurgaon,
Haryana, India
Editors and Contributors
1
Advances inDevelopment
ofPharmaceutical Products
KeertiJain
, SofiyaTarannum, GijithK.Mohan,
ManishaPatel, AnchalPathak, ParthPatel, VineetK.Jain,
AshishBaldi, andHarvinderPopli
Abstract
The process of pharmaceutical product development may be classied into four
stages including preformulation, prototype development, scale-up studies and
commercialisation of pharmaceutical formulations. Pharmaceutical product
development begins with the estimation of physicochemical properties of new
chemical entity with druggable properties. These physicochemical properties are
determined in the rst stage and one of the foremost steps in the development of
pharmaceutical formulation, i.e. preformulation studies. Preformulation studies
aid in determining the possible obstacles which could be anticipated in pharma-
ceutical formulationdevelopment; further, it also assists in identifying the appro-
priate dosage form and route of administration to develop a prototype, which
could be nally developed in a safe, effective and stable pharmaceutical product
for the new drug molecule. In this chapter, we have discussed advances in phar-
maceutical product development as well as about all these four important stages,
i.e. preformulation, prototype development, scale-up studies and commercialisa-
tion of pharmaceutical formulations involved in pharmaceutical product
development.
K. Jain (*) · S. Tarannum · G. K. Mohan · M. Patel · A. Pathak · P. Patel
Drug Delivery and Nanomedicine Research Laboratory, Department of Pharmaceutics,
National Institute of Pharmaceutical Education and Research (NIPER)—Raebareli,
Lucknow, Uttar Pradesh, India
e-mail: keertijain.02@niperraebareli.edu.in
V. K. Jain · H. Popli
Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research
University (DPSRU), New Delhi, India
A. Baldi
Pharma Innovation Lab, Department of Pharmaceutical Sciences and Technology,
Maharaja Ranjit Singh Punjab Technical University, Bathinda, Punjab, India
2
Keywords
Preformulation · Efcacy · Stability · Prototype · Commercialisation · Pilot plant
· Scale-up
1.1 Introduction
Pharmaceutical product development is becoming interdisciplinary day by day with
the involvement of techniques of biotechnology, nanotechnology, etc. Therefore,
researchers are investing substantial efforts in developing a product in a systematic
manner with the involvement of optimisation and evaluation. Thepharmaceutical
product development process is generallyclassied into four stages including prefor-
mulation, prototype development, scale-up studies and commercialisation of phar-
maceutical formulations. Pharmaceutical products must comply with the guidelines
issued by regulatory authorities so that its quality, efcacy and safety can be ensured
(Amarji etal. 2018). The development of pharmaceutical products is carried outunder
the supervision of the formulation scientists, who are expert and knowledgeable
enough to produce novel pharmaceutical products covering all the steps, starting
from the conceptualisation of product to its nal packaging that can enter the market
and boost the pharmaceutical industry (Destro and Barolo 2022). Pharmaceutical
product development is evolving day by day due to inclusion of both the conven-
tional and novel techniques and approaches of several elds like biotechnology,
molecular biology and genetics apart from the core pharma, so that unmet medical
challenges can be tackled in a better way by using the new therapies (Ojha etal. 2021).
A detailed information and data regarding the properties of active pharmaceuti-
cal ingredients (APIs), excipients, the interaction between all the elements of the
pharmaceutical products and manufacturing techniques are collected in the initial
phases of research that together are called as the preformulation studies. As the
novel drug development is time- and resource-consumingprocess, the generic prod-
ucts and improvised dosage form developments are preferred as their safety as well
as efcacy database is already available, contributing to their rapid development
along with the exemption of clinical trials (Patravale etal. 2016). Recent advance-
ments in pharmaceutical research and development highlight the development of
new analytical technologies that supports the preformulation research like prefor-
mulation parameters, stability studies, chiral purity analysis of therapeutic agents,
chiral swapping probabilities, preformulation solvent selection and equilibrium and
intrinsic solubility analysis of main compounds in suitable solvents. These analyti-
cal technologies are important as they give correct ndings in no time, which can be
explored by the formulation scientists (Bharate and Vishwakarma 2013).
After the preformulation studies, prototype development is the next step in the
development of pharmaceutical products. Ideas are needed that are then conceptu-
alised, and as far as the pharmaceutical products are concerned, it basically revolves
around the product’s efcacy,stability and safety. Like a seed, the concept is then
germinated by experimental laboratory work into a prototype (Sathish etal. 2016).
The development of prototype is one of the essential steps, needed to be taken
K. Jain etal.
3
while developing a novel product as it includes the basic working model of the
product that will be nalised and transformed into the nal product. Prototype
development is categorised into four phases, i.e. (i) identication of the basic
requirements for the product development, (ii)preparation and implementation of
the design to meet the basicrequirements identied in phase 1, (iii) experiments
with the prototype, and (iv) revision of prototype to accomplish basic require-
ments. Prototype development of all the dosage forms like parenteral, solid oral,
topical, transdermal and inhalational is usually carried out so that they can be
moulded into their best version without any defects and aws.
As the nal pharmaceutical products at the lab scale are obtained after the pre-
formulation studies and prototype development, the products are needed to be
scaled up for fullling the demands of the patients (Raval et al. 2018). Large
scalesuccess of pharmaceutical productsdepends on the tactic that how well the
small-scale experimentation has been performed using the facility of pilot plant and
correct application of scale-up techniques. The pilot plant is a small-scale process
plant designed to obtain information that can be used in industrial-scale processes.
They allow us to see the feasibility of industrial-scale designs and processes, thus
reducing the initial investment cost (Strovel etal. 2016).
Nevertheless, a huge gap exists between small scale and large scale because of
the limited suitable scale-up methodologies that can be seen in case of nano-
formulations like liposomes, dendrimers, polymeric nanoparticles, etc. Several
advancements are taking place in scale-up processes, because of which many nano-
formulations came into the market. The scale-up should abide by the rules of current
good manufacturing practices(cGMP),which ensures that the necessary measures
are taken for production as well as quality control so that production processes and
testing are properly dened, validated, reviewed and documented. Along with that,
by using the GMP guidelines, ofcials also inspect the working personnel, sites and
materials and make sure that the developed pharmaceutical products are safe and
efcacious (WHO 2024). GMP dictates how manufacturers handle the distribution
of their products to ensure they maintain quality and reach patients in a safe state.
This might involve regulations for storage conditions, transportation protocols and
traceability throughout the supply chain. By incorporating the legal components,
GMP fosters a system where quality and safety are prioritised at every stage, from
raw materials to the nal product reaching the patient (FDA, 2024).
Pharmaceutical companies submit a detailed application to the relevant regulatory
body. This application contains comprehensive data on the drug, including its chemi-
cal composition, manufacturing processes, preclinical animal testing results and,
most importantly, clinical trial data from all phases. Regulatory agencies meticu-
lously evaluate the submitted data. The regulatory approval process is often lengthy
and intricate. This is because the stakes are incredibly high—a drug that is not safe
or effective can have devastating consequences for patients. The extensive documen-
tation and thorough evaluation ensure potential risks are attenuated/minimised and
the drug’s benets are well established before it reaches the public (Moini etal. 2023).
Marketing campaigns and sales representatives are the critical part of commer-
cialisation that play crucial role in raising awareness about the pharmaceutical prod-
ucts among healthcare professionals and patients who may get benet from it.
1 Advances inDevelopment ofPharmaceutical Products
4
However, ethical guidelines ensure that these efforts are truthful and balanced,
focusing on the product’s benets and potential drawbacks. Strategies are carefully
crafted to target the appropriate audience. This might involve medical journals, edu-
cational conferences for healthcare providers or patient advocacy groups (Amarji
etal. 2018). In an era of online marketing and articial intelligence (AI), the com-
mercialisation of pharmaceutical products by managing their life cycle in the best
possible manner is way easier with better reach as compared to the prior decades
(Shanbhogue etal. 2021). Post-marketing surveillance and pharmacovigilance also
come into action as this ongoing process involves actively monitoring the drug’s
safety prole once it is in the market. It includes collecting and analysing data on
adverse events experienced by patients. This might involve modifying prescribing
guidelines, issuing warnings or even recalling the drug if necessary. AI automates
tedious tasks like data extraction, freeing up human reviewers to focus on complex
cases or analysis. AI reduces human error in data extraction and analysis, leading to
more reliable data for identifying safety concerns. AI can analyse vast amounts of
data quickly, allowing for earlier detection of potential safety issues with medica-
tions (Schmider etal. 2019).
1.2 Preformulation Studies
Technical understanding of different characteristics of a drug molecule is crucial for
designing the appropriate dosage form with optimum therapeutic efcacy and
patient compliance. Preformulation, the cornerstone of this process, provides the
fundamental scientic information for formulation development. It is the initial
step, where parameters are investigated before the pharmaceutical product is formu-
lated into an appropriate dosage form. This is not just a step but a crucial foundation
for the entire process. A variety of study sets focused to explore the physical and
chemical characteristics of a novel moleculeare included in preformulationstudies.
These physical and chemical characteristics signicantly impact the medication’s
biofate.
Strong proof-of-concept and preclinical studies are necessary to understand the
characteristics of the therapeutically active agent and any pertinent additives that
may impact the nal formulation and drug performance. Scientists are guided in this
process by their deep understanding and comprehensive knowledge of the prefor-
mulation parameters of the drug (Ahirwar and Shukla 2023).Some of the essential
preformulation parameters are discussed in the following subsections:
1.2.1 Solubility
The solubility of therapeutically active agents plays a signicant role in developing
pharmaceutical products. Poor solubility can also negatively impact the compound’s
invivo behaviour and complicate test design. As a result, poor solubility could pre-
vent development of new treatments. Lattice energy, weak bonding forces,
K. Jain etal.
5
co- solvency, pH, additives, dielectric constant, hydrotrophy, complexation, tem-
perature, lipophilicity, ionisation potential, solubilisation by surfactant, pressure
and molecular volume are some of the factors that generally affect solubility of drug
molecules. These criteria might help to develop the nal formulation with reduced
possibilities of drug failure if they were thoroughly examined during preformula-
tion studies (Ahirwar and Shukla 2023).
In conclusion, factors such as temperature, pH levels, solvent system, diluents,
additives and the physical state of the drug molecules could change solubility pro-
le of drug. Adequate water solubility is necessary for therapeutic efcacy in a
normal pH range of 1–8. If the solubility of a therapeutically active agent is not
optimal, signicant efforts are required to increase it. Poor solubility, dened as
10mg/mL, can lead to incomplete or irregular absorption under physiological con-
ditions (Bandopadhyay etal. 2018;Ahirwar and Shukla 2023).
1.2.2 Partition Coefficient
The partition coefcient (log P) is the ratio of unionised drug distributed between
the organic and aqueous phases. The ability of drug moleculeto cross the lipidic
membrane is provided by the oil-water partition coefcient. For the best possible
intestinal absorption of drug molecules, an optimised lipophilic/hydrophilic balance
is one of the most important elements as biological membranes are lipidic, but the
outer layer is coated with a hydrophilic mucus membrane. Hence, the partition coef-
cient value signicantly impacts how much of a drug will get absorbed and reach
the systemic circulation.
Equal distribution of drugin water and partitioning solvent is represented by a
log P value of 0. Higher lipidic solubility is indicated by a log P value larger than 1,
while higher water solubility is indicated by a value less than 1. A suitable
hydrophilic- lipophilic balance is required for maximum solubility and absorption.
Since it is nearly impossible to determine the log P value in a biological system,
several techniques are available to calculate the partition coefcient of a molecule
invitro. These techniques include the following methods: shake ask, countercur-
rent/lter probe and software-based computation methods. The shaking ask
method, which uses the octanol-water system to assess the partitioning characteris-
tics of drugs, is widely used (Bandopadhyay etal. 2018; Barbosa etal. 2019; Bastin
etal. 2000). Octanol is chosen as the partitioning solvent for several reasons, as
mentioned below:
• Because it has a polar head and a nonpolar tail, octanol is thought to mimic the
lipoidal nature of biological membranes.
• It is an organic compound that is immiscible with water, though some water is
expected to be present in the polar head portion.
• Solubility prole of most of the drug molecules in octanolresemble their lipo-
philicity (Bastin etal. 2000).
1 Advances inDevelopment ofPharmaceutical Products